<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699631</url>
  </required_header>
  <id_info>
    <org_study_id>PRO32694</org_study_id>
    <nct_id>NCT03699631</nct_id>
  </id_info>
  <brief_title>PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant</brief_title>
  <official_title>PROACTIVE: Prevention of Acute and Chronic GVHD Using TocIlizumab in Combination With Standard GVHD Prophylaxis After allogEneic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II open-label trial designed to evaluate the efficacy of tocilizumab in&#xD;
      improving GVHD-free/relapse-free survival (GRFS) after allogeneic hematopoietic cell&#xD;
      transplantation (alloHCT) for hematologic malignancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research team earlier hypothesized and demonstrated that tocilizumab could attenuate the&#xD;
      incidence of acute GVHD (aGVHD) after myeloablative conditioning (MAC) and reduced intensity&#xD;
      conditioning (RIC) Allogeneic hematopoietic cell transplantation (alloHCT), using matched&#xD;
      sibling or unrelated donor. In this study, the research team hypothesizes that longer term&#xD;
      interleukin 6 (IL-6) inhibition through treatment with tocilizumab by repeated dosing would&#xD;
      mediate a beneficial effect not only on the risk of aGVHD, but also on chronic GVHD. This&#xD;
      will be achieved by administering an additional dose of tocilizumab at Day +100 post-alloHCT,&#xD;
      besides the pretransplant dose, as done in our previous clinical trial, thereby providing&#xD;
      total prophylaxis against both acute and chronic GVHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with GVHD/relapse-free (GRFS) survival</measure>
    <time_frame>Day 365</time_frame>
    <description>GRFS is defined as survival without grade III-IV acute GVHD, systemic therapy requiring chronic GVHD, relapse, or death at 12 months after matched related/unrelated donor bone marrow or peripheral blood alloHCT using myeloablative conditioning (MAC). Patients who are alive without GVHD will be censored at the last follow-up.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Tacrolimus/Methotrexate/Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant.&#xD;
Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11.&#xD;
Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.</description>
    <arm_group_label>Tacrolimus/Methotrexate/Tocilizumab</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.</description>
    <arm_group_label>Tacrolimus/Methotrexate/Tocilizumab</arm_group_label>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.</description>
    <arm_group_label>Tacrolimus/Methotrexate/Tocilizumab</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Patients with any hematologic malignancy for which alloHCT is indicated. Patients with&#xD;
             acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) must be in&#xD;
             complete remission at the time of alloHCT(&lt;5% blasts in the bone marrow, normal&#xD;
             maturation of all cellular components in the bone marrow and absence of extramedullary&#xD;
             disease).&#xD;
&#xD;
          3. Myeloablative conditioning (MAC) regimen, based on Center for International Blood and&#xD;
             Marrow Transplant Research (CIBMTR) criteria.&#xD;
&#xD;
          4. T cell-replete peripheral blood graft.&#xD;
&#xD;
          5. Patients must have a matched related or unrelated donor (at least 6/6 match at human&#xD;
             leukocyte antigens (HLA) -A, -B and -C for related donors and at least 8/8 match at&#xD;
             HLA-A, -B, -C and -DRB1 for unrelated donors).&#xD;
&#xD;
          6. Cardiac function: Left ventricular ejection fraction ≥45% for myeloablative&#xD;
             conditioning.&#xD;
&#xD;
          7. Estimated creatinine clearance ≥40 mL/minute (using the Cockcroft-Gault formula and&#xD;
             actual body weight).&#xD;
&#xD;
          8. Pulmonary function: Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥40%&#xD;
             (adjusted for hemoglobin) and Forced Expiratory Volume (FEV1) ≥50%.&#xD;
&#xD;
          9. Liver function: total bilirubin &lt;3 x upper limit of normal and alanine&#xD;
             aminotransferase (ALT) / aspartate aminotransferase (AST) &lt;5 x upper normal limit.&#xD;
&#xD;
         10. Signed informed consent: Voluntary written consent must be given before patient&#xD;
             registration and performance of any study related procedure not part of standard&#xD;
             medical care, with the understanding that consent may be withdrawn by the patient at&#xD;
             any time without prejudice to future medical care.&#xD;
&#xD;
         11. Female patient: A negative pregnancy test will be required for women of child bearing&#xD;
             potential. Breast-feeding or lactation is not permitted.&#xD;
&#xD;
         12. Planned posttransplant maintenance therapy is allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior allogeneic HCT.&#xD;
&#xD;
          2. Active central nervous system (CNS) involvement with malignancy.&#xD;
&#xD;
          3. Patients receiving cord blood or haploidentical allograft.&#xD;
&#xD;
          4. Patients undergoing in vivo or ex vivo T cell-depleted alloHCT.&#xD;
&#xD;
          5. Karnofsky Performance Score &lt;60%.&#xD;
&#xD;
          6. Patients with uncontrolled bacterial, viral or fungal infections (currently on&#xD;
             treatment and with progression of infectious disease or no clinical improvement) at&#xD;
             time of enrollment.&#xD;
&#xD;
          7. Active hepatitis B or C virus infection or known human immunodeficiency virus (HIV)&#xD;
             positive.&#xD;
&#xD;
          8. Prior intolerance or allergy to tocilizumab.&#xD;
&#xD;
          9. Use of rituximab, alemtuzumab, anti-thymocyte globulin (ATG) or other monoclonal&#xD;
             antibody planned as part of conditioning regimen for GVHD prophylaxis.&#xD;
&#xD;
         10. History of diverticulitis, Crohn's disease or ulcerative colitis.&#xD;
&#xD;
         11. History of demyelinating disorder.&#xD;
&#xD;
         12. Any current uncontrolled cardiovascular conditions, including uncontrolled ventricular&#xD;
             arrhythmias, New York Heart Association (NYHA) class III or IV congestive heart&#xD;
             failure, uncontrolled angina, or electrocardiographic evidence of active ischemia or&#xD;
             active conduction system abnormalities.&#xD;
&#xD;
         13. Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment according to this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saurabh Chhabra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Saurabh Chhabra</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

